" data-display-label="0" data-show-count="1" data-bookmark-label="Save" data-bookmarked-label="Saved" data-loggedin="0" ...

(Reuters) -The U.S. Food and Drug Administration has approved Regeneron's cancer therapy, the company said on Wednesday, ...

Anne Wojcicki's nonprofit, TTAM Research Institute, has received court approval to acquire 23andMe, the genetic testing ...

Co-founder Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron's offer for the DNA-testing company in a bankruptcy auction.

New York and more than two dozen other US states sued 23andMe to challenge the sale of its customers’ private information after the genetic testing company filed for bankruptcy in March.

Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron is paying Hansoh $80 million upfront for a phase 3-stage GLP-1/GIP agonist the companies believe can hold its own against Lilly’s Zepbound.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data while continuing genome testing services.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.